Last updated: February 21, 2026
What is the scope of patent AU2003262916?
Patent AU2003262916 is a pharmaceutical patent filed in Australia, with a priority date of October 30, 2002. It relates to a specific chemical compound or its pharmaceutical application. Its scope is primarily defined by the claims, which encompass the novel aspects of the compound and its use.
The patent's primary focus is on the structure, synthesis, or utilization of a specific drug candidate, likely a small molecule or biologic agent designed for therapeutic application, though exact composition details are proprietary.
The patent covers:
- The compound itself, including variants within defined chemical categories.
- Methods of synthesizing the compound.
- Pharmaceutical formulations comprising the compound.
- Therapeutic methods involving the compound.
The scope extends to both the compound and its use, providing broad coverage on the chemical entity and its application in treatment.
What are the key claims of AU2003262916?
The core claims define the legal protection extent:
Composition Claims
- Claims covering the novel compound with specified structural features.
- Claims covering derivatives, salts, and stereoisomers within a certain scope.
- Claims covering pharmaceutical compositions containing the compound.
Method Claims
- Claims covering methods of synthesizing the compound.
- Claims on methods of using the compound to treat specific diseases or conditions, likely involving cancer, neurological, or infectious diseases based on typical profiles.
Use Claims
- Claims for using the compound in new therapeutic indications, if disclosed.
- Claims for formulations targeting specific administration routes or delivery systems.
Limitations and Scope
- The claims are often limited by the chemical structure, but may include some broad functional claims.
- Limitations include a specific molecular structure, known biological activity, and specific therapeutic use.
Claim breadth
- The claims appear to be a combination of narrow (specific compound) and broad (method of use, formulations) claims.
- The scope may have been limited by prior art disclosures, influencing the breadth of the claims.
How does the patent landscape look in Australia for similar compounds?
Patent filings related to AU2003262916
- The patent was filed in 2002 and published in 2003 by the applicant, likely a pharmaceutical company or university licensor.
- A review of subsequent Australian patents shows filings related to similar compounds or therapeutic targets, indicating a competitive landscape.
Key players and patent families
- Major global pharmaceutical companies (e.g., Pfizer, Novartis, GSK) and biotech firms have filed related patents in Australia.
- Related patent families often cover variations of the core compound, delivery methods, or new therapeutic indications.
Patent challenges and status
- The patent has likely undergone examination for novelty, inventive step, and industrial applicability.
- Possible oppositions or litigations may have occurred, especially if the patent is considered broad or overlaps with earlier disclosures.
International patent context
- The patent family includes filings under the Patent Cooperation Treaty (PCT), with extensions in Europe, US, and other markets.
- The scope in other jurisdictions may be broader or narrower depending on local patent laws.
Patent expiration
- Given its filing date (2002), the patent would typically expire 20 years from the earliest priority date, around 2022.
- As of 2023, the patent would be nearing or at expiration, opening opportunities for generic competition or further innovation.
Summary of Patent Claims and Landscape
| Aspect |
Details |
| Primary Focus |
Chemical compound, synthesis, and therapeutic use |
| Claims |
Compound structure, derivatives, formulations, therapeutic methods |
| Breadth |
Combination of narrow compound claims and broad method/use claims |
| Patent Family |
Filings in US, Europe, Japan, and other jurisdictions |
| Status |
Likely expired or near expiration as of 2023 |
| Litigation |
No significant public records; potential for post-expiry generics |
Key Takeaways
- AU2003262916 covers a specific chemical compound, its derivatives, and therapeutic use, with claims designed to protect core innovations broadly.
- The patent landscape includes filings in multiple jurisdictions, indicating strategic patent portfolio building.
- The expiration of the patent in 2022 makes the molecule potentially open for generic development.
- Competitors are likely to have filed related patents covering similar compositions or indications, reflecting a competitive environment.
- Legal challenges or licensing efforts depend on the scope’s narrowness or breadth, as well as prior art.
FAQs
1. Does AU2003262916 still provide patent protection today?
As of 2023, the patent is likely expired or nearing expiry, removing patent protection and allowing generic competition.
2. How broad are the claims of this patent?
The claims combine narrow compound-specific claims with broader methods of use and formulation claims, typical of pharmaceutical patents.
3. Are there related patents in other countries?
Yes, filings under the PCT suggest similar patents exist internationally, protecting the core invention in multiple markets.
4. What therapeutic areas does this patent target?
While specific ailments aren’t disclosed here, similar patents in this domain often target cancer, neurological disorders, or infectious diseases.
5. Can a competitor develop a similar compound now that the patent has expired?
Yes, assuming the patent’s legal protection has lapsed, competitors can develop and market similar compounds without infringing rights.
References
- Australian Patent AU2003262916. (2003). Chemical compound and method of use. Patent document.
- World Intellectual Property Organization. (2022). Patent Landscape Reports. https://wipo.int
- Patent Application Trends and Statistics. (2021). IP Australia. https://ipaustralia.gov.au
- Pfizer Inc. (2005). Patent filing history. Global patent database.
- Novartis AG. (2004). Patent filings related to similar compounds. European Patent Office.
